Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
ASMB Listed as a key company in the MSA market, but no specific details about its pipeline or performance are provided in the article. IONS Listed as a key company in the MSA market, but the article does not provide specific details on its pipeline or performance. BIIB Mentioned as a key company in the MSA and Parkinson's Disease pipeline, but no specific details on its current performance or pipeline are provided. ALT Listed as a key company in the MSA market, but the article does not provide specific details on its pipeline or performance. TEVA Mentioned as a key company in the MSA market, but the article does not provide specific details on its pipeline or performance. ANVS Listed as a key company in the Parkinson's Disease market and pipeline, but the article does not provide specific details on its performance. SUPN Mentioned as a key company in the Parkinson's Disease market, but the article does not provide specific details on its pipeline or performance. ABBV Listed as a key company in the Parkinson's Disease market and pipeline, but the article does not provide specific details on its performance. AVXL Listed as a key company in the Parkinson's Disease pipeline, but the article does not provide specific details on its performance. MRK Listed as a key company in the Psychosis in Parkinson's and Alzheimer's Disease market, but the article does not provide specific details on its performance. KAR Mentioned as a key company in the Psychosis in Parkinson's and Alzheimer's Disease market, but the article does not provide specific details on its performance. VNDA Listed as a key company in the Psychosis in Parkinson's and Alzheimer's Disease market, but the article does not provide specific details on its performance.

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight New york, USA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The multiple system atrophy clinical trial analysis report delivers important insights into ongoing research of 24+ pipeline multiple system atrophy drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Multiple System Atrophy Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for multiple system atrophy across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the multiple system atrophy domain.

Multiple System Atrophy Clinical Trial Analysis Summary

Request a sample and discover the recent advances in multiple system atrophy treatment @ https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight

What is Multiple System Atrophy?

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by the gradual deterioration of nerve cells in multiple regions of the brain that control movement, balance, coordination, and autonomic functions. It is classified as an atypical Parkinsonian disorder and is marked by a combination of symptoms resembling Parkinson's Disease, cerebellar ataxia, and autonomic dysfunction. Patients with MSA may experience muscle rigidity, slowed movements, impaired balance, difficulty walking, speech and swallowing problems, as well as autonomic symptoms such as orthostatic hypotension, urinary incontinence, erectile dysfunction, and impaired sweating. The disease is associated with the abnormal accumulation of alpha-synuclein protein within glial cells of the central nervous system, leading to progressive neuronal damage. MSA is generally categorized into two subtypes: MSA-P, where Parkinsonian symptoms predominate, and MSA-C, where cerebellar symptoms are more prominent. Although the exact cause remains unknown, MSA is a rapidly progressive condition with no curative treatment currently available, and management focuses on alleviating symptoms and improving quality of life.

Find out more about treatment for multiple system atrophy @ Multiple System Atrophy New Treatment

A snapshot of the Pipeline Multiple System Atrophy Drugs mentioned in the report:

Learn more about the multiple system atrophy research @ Multiple System Atrophy Clinical Trials

As per Stuti Mahajan, consulting manager at DelveInsight, the multiple system atrophy pipeline is increasingly diversified, encompassing a broad range of therapeutic modalities and mechanisms of action beyond conventional approaches. While intravenous alpha-synuclein-targeting monoclonal antibodies such as Amlenetug remain among the most advanced candidates, the pipeline is expanding to include oral small molecules, intrathecal and intracerebral cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors such as PMN442. This diversified pipeline is expected to drive a transition from symptomatic management toward disease-modifying treatment strategies, with therapies targeting alpha-synuclein pathology, neuroprotection, and neuronal regeneration likely to shape the future treatment landscape. As late-stage candidates advance toward commercialization, the MSA market is anticipated to become increasingly competitive, with innovative disease-modifying therapies establishing new standards of care and significantly expanding therapeutic options for patients.

Recent Developments in Multiple System Atrophy Treatment Space

Scope of the Multiple System Atrophy Pipeline Report

Dive deep into rich insights for multiple system atrophy cure, visit @ Multiple System Atrophy News

Table of Contents

For further information on the multiple system atrophy clinical trials, reach out @ Multiple System Atrophy Medication

Related Reports

Multiple System Atrophy Market

Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MSA companies, including H Lundbeck A/S, Brain Neurotherapy Bio, Inc., Asklepios BioPharmaceutical, Inc., Theravance Biopharma, Ono Pharmaceutical Co. Ltd, Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, and others.

Parkinson’s Disease Market

Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, and others.

Parkinson’s Disease Clinical Trial Analysis

Parkinson’s Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson’s disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Modag, Annovis Bio, BioVie, United Neuroscience, Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical, Cerevance Beta, Nobilis Therapeutics, BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology, NeuroDerm, Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Takeda, Xoc Pharmaceuticals, Sumitomo Pharma, XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, 1ST Biotherapeutics, Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Alkahest, Kissei Pharmaceutical, and others.

Parkinson's Disease Levodopa-Induced Dyskinesia Market

Parkinson's Disease Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease levodopa-induced dyskinesia companies, including PharmaTher Inc., Neurolixis SAS, Gala Laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others.

Psychosis in Parkinson’s and Alzheimer’s Disease Market

Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.